Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $42.1700 (3.54%) ($42.1700 - $43.5300) on Mon. Aug. 22, 2011. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.24% (three month average) | RSI | 14 | Latest Price | $42.1700(3.54%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV declines -1.9% a day on average for past five trading days. | Weekly Trend | VBIV declines -9.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(20%) REMX(14%) EEM(11%) FXI(11%) OIH(11%) | Factors Impacting VBIV price | VBIV will decline at least -2.12% in a week (0% probabilities). TLT(-5%) TIP(2%) USO(3%) XLU(4%) SHY(4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.12% (StdDev 4.24%) | Hourly BBV | 0 () | Intraday Trend | -3.1% | | | |
|
1 - 5 Day Possible Target | $22.45(-46.76%) | Resistance Level | $49.18 | 5 Day Moving Average | $42.66(-1.15%) | 10 Day Moving Average | $44.6(-5.45%) | 20 Day Moving Average | $49.18(-14.25%) | To recent high | -34% | To recent low | 3.5% | Market Cap | $9.726b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |